Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

ABSTRACT:

Background

Ebola virus causes a hemorrhagic fever syndrome that is associated with high mortality in humans. In the absence of effective therapies for Ebola virus infection, the development of a vaccine becomes an important strategy to contain outbreaks. Immunization with DNA and/or replication-defective adenoviral vectors (rAd) encoding the Ebola glycoprotein (GP) and nucleoprotein (NP) has been previously shown to confer specific protective immunity in nonhuman primates. GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine.

Methods and findings

To address this question, we have explored the efficacy of mutant GPs from multiple Ebola virus strai

SUBMITTER: Sullivan NJ 

PROVIDER: S-EPMC1459482 | biostudies-literature | 2006 Jun

REPOSITORIES: biostudies-literature